Treatment of Primary Liver Tumors and Liver Metastases, Part 1: Nuclear Medicine Techniques
- PMID: 30072501
- DOI: 10.2967/jnumed.116.186346
Treatment of Primary Liver Tumors and Liver Metastases, Part 1: Nuclear Medicine Techniques
Abstract
90Y radioembolization is an increasingly used treatment for both primary and metastatic malignancy in the liver. Understanding the biophysical properties, dosing concerns, and imaging appearance of this treatment is important for interventional radiologists and nuclear medicine physicians to provide important therapy. 90Y radioembolization is efficacious and safe, although the possibility of complications does exist. This article provides a comprehensive in-depth discussion about the indications for 90Y radioembolization, reviews the role of preprocedural angiography and 99mTc-macroaggregated albumin scans, illustrates different dosing techniques, compares and contrasts resin and glass microspheres, and describes potential complications.
Keywords: 90Y radioembolization; MAA; hepatocellular carcinoma; liver, cancer.
© 2018 by the Society of Nuclear Medicine and Molecular Imaging.
Similar articles
-
A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.J Vasc Interv Radiol. 2014 Feb;25(2):277-87. doi: 10.1016/j.jvir.2013.11.007. J Vasc Interv Radiol. 2014. PMID: 24461133
-
Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres.Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):559-75. doi: 10.1007/s00259-015-3157-8. Epub 2015 Sep 4. Eur J Nucl Med Mol Imaging. 2016. PMID: 26338177 Free PMC article. Review.
-
Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors.J Nucl Med. 2015 Nov;56(11):1654-60. doi: 10.2967/jnumed.115.162685. Epub 2015 Aug 27. J Nucl Med. 2015. PMID: 26315830
-
Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.J Nucl Med. 2012 Feb;53(2):255-63. doi: 10.2967/jnumed.111.094235. J Nucl Med. 2012. PMID: 22302962
-
[Nuclear medicine techniques for selective internal radiotherapy of liver cancer].Ugeskr Laeger. 2017 Jan 2;179(1):V09160629. Ugeskr Laeger. 2017. PMID: 28074772 Review. Danish.
Cited by
-
90Y post-radioembolization clinical assessment with whole-body Biograph Vision Quadra PET/CT: image quality, tumor, liver and lung dosimetry.Eur J Nucl Med Mol Imaging. 2024 Jun;51(7):2100-2113. doi: 10.1007/s00259-024-06650-9. Epub 2024 Feb 13. Eur J Nucl Med Mol Imaging. 2024. PMID: 38347299 Free PMC article.
-
The Future of Interventions for Stage IV Colorectal Cancers.Clin Colon Rectal Surg. 2023 Feb 7;37(2):114-121. doi: 10.1055/s-0043-1761624. eCollection 2024 Mar. Clin Colon Rectal Surg. 2023. PMID: 38327731 Free PMC article. Review.
-
In Vivo Models for the Performance and Safety of BAT-90, a Novel 90-Yttrium-based Internal Radiotherapy Platform.In Vivo. 2022 Sep-Oct;36(5):2052-2060. doi: 10.21873/invivo.12931. In Vivo. 2022. PMID: 36099118 Free PMC article.
-
Mechanistic connections between mitochondrial biology and regulated cell death.Dev Cell. 2021 May 3;56(9):1221-1233. doi: 10.1016/j.devcel.2021.03.033. Epub 2021 Apr 21. Dev Cell. 2021. PMID: 33887204 Free PMC article. Review.
-
High quality imaging and dosimetry for yttrium-90 (90Y) liver radioembolization using a SiPM-based PET/CT scanner.Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2426-2436. doi: 10.1007/s00259-021-05188-4. Epub 2021 Jan 14. Eur J Nucl Med Mol Imaging. 2021. PMID: 33443618
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
